Beloranib

CAT: 0804-HY-14811-01Size: 250 µgDry Ice: NoHazardous: No

1 / 1

CAT#:0804-HY-14811-01Size:250 µg

Selected

24/48H Stock Items & 2 to 6 Weeks non Stock Items.

Quick Request Actions

Description

Beloranib is a fumagillin-class methionine aminopetidase-2 (MetAP2) inhibitor. Beloranib decreases food intake, body weight, fat mass, and the size of adipocytes[1][2][3][4].

CAS Number

251111-30-5

Product Name Alternative

ZGN-440; CKD-732 (free base)

UNSPSC

12352005

Target

MetAP

Type

Reference compound

Related Pathways

Metabolic Enzyme/Protease

Field of Research

Metabolic Disease

Assay Protocol

https://www.medchemexpress.com/beloranib.html

Solubility

10 mM in DMSO

Smiles

C[C@]1([C@H](O1)C/C=C(C)\C)[C@]2([H])[C@]3(CC[C@H]([C@H]2OC)OC(/C=C/C4=CC=C(C=C4)OCCN(C)C)=O)CO3

Molecular Formula

C29H41NO6

Molecular Weight

499.64

References & Citations

[1]Lee HS, Choi WK, Son HJ, et al. Absorption, distribution, metabolism, and excretion of CKD-732, a novel antiangiogenic fumagillin derivative, in rats, mice, and dogs. Arch Pharm Res. 2004;27 (2) :265-272. |[2]Elfers CT, Roth CL. Robust Reductions of Excess Weight and Hyperphagia by Beloranib in Rat Models of Genetic and Hypothalamic Obesity. Endocrinology. 2017;158 (1) :41-55. |[3]Kim YM, An JJ, Jin YJ, et al. Assessment of the anti-obesity effects of the TNP-470 analog, CKD-732. J Mol Endocrinol. 2007;38 (4) :455-465. |[4]Kim EJ, Shin WH. General pharmacology of CKD-732, a new anticancer agent: effects on central nervous, cardiovascular, and respiratory system. Biol Pharm Bull. 2005;28 (2) :217-223.

Shipping Conditions

Room temperature

Scientific Category

Reference compound1

Clinical Information

Phase 3

Alternative Products

Catalog	Name
TRC-B131280-1MG	Beloranib
T89217-01	Beloranib hemioxalate
A13870-5	Beloranib 5mg
A13870-10	Beloranib 10mg
442212-01	Beloranib discontinued
TRC-B131282-5MG	Beloranib-d6

Beloranib

Alternative Products

Popular Products